Elaine Siegfried, MD, of Saint Louis University School of Medicine discusses the use of biologics to treat atopic dermatitis (AD) and how they differ from other treatments.
EDA loss or dysfunction precludes binding to its endogenous EDA1 receptor, and downstream development of teeth, hair, nails, and skin adnexae, most notably eccrine glands.
In this interview segment, Siegfried discussed the major points she hopes clinicians take away from her Revolutionizing Atopic Dermatitis conference talk regarding eczema in infants.
Siegfried spoke on the subjects covered in her presentation at the Revolutionizing Atopic Dermatitis conference, specifically the different conditions that can mirror eczema in infancy.